PLEKHG3

Across TCGA pan-cancer cohorts, PLEKHG3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLEKHG3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PLEKHG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHG3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, LUSC, and SCLC are the cancer types where PLEKHG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.151	0.669	.005	18	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.144	0.525	.005	12	view →
PRAD	DFS	Median	All	0.617	0.886	.024	6	view →
UCEC	DFS	Median	All	0.955	0.827	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLEKHG3–CESC (OS)

Open the CESC breakdown →